Insider · CIK 0001565536
Daniel H Schneiderman
Files at KTTA (Pasithea Therapeutics Corp.). First filing -, latest -.
In brief
Daniel H Schneiderman files SEC Form 4 as CFO at KTTA (Pasithea Therapeutics Corp.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Daniel H Schneiderman has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | KTTA Pasithea Therapeutics Corp. | AGrant or award Stock Option (right to buy)derivative | +1,129,323 | $0.00 | $0 | 1,129,323 | May 5, 2026 |
| Nov 28, 2025 | KTTA Pasithea Therapeutics Corp. | AGrant or award Common Stock | +26,667 | $0.75 | $20k | 26,667 | Dec 1, 2025 |
| Oct 24, 2025 | KTTA Pasithea Therapeutics Corp. | AGrant or award Stock Option (right to buy)derivative | +317,266 | $0.00 | $0 | 317,266 | Oct 27, 2025 |
Questions about Daniel H Schneiderman
Answered from the filings on this page, as of the latest one.
Is Daniel H Schneiderman buying or selling?
Daniel H Schneiderman has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Daniel H Schneiderman's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Daniel H Schneiderman has 0.
Where does Daniel H Schneiderman file Form 4?
Daniel H Schneiderman has filed Form 4 at KTTA (Pasithea Therapeutics Corp.) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.